Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

The Impact of Vitamin D Supplementation on Pregnant Women With the Risk of GDM

Not Applicable

Not yet recruiting

Conditions: Gestational Diabetes Mellitus

Interventions: Drug: Placebo supplementation
Drug: Vitamin D supplementation

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-29

Lead Sponsor: IIMC, Riphah International University, Pakistan

Target Recruit Count: 350

Registration Number: NCT06139133

Locations: 🇵🇰
Pakistan Railway Hospital, Rawalpindi, Punjab, Pakistan

Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura

Early Phase 1

Not yet recruiting

Conditions: Immune Thrombocytopenia

Interventions: Drug: VIT D

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-10

Lead Sponsor: Mansoura University

Target Recruit Count: 30

Registration Number: NCT06073925

Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.

Phase 4

Recruiting

Conditions: Osteoporosis in Postmenopausal Women

Interventions: Drug: Eldecalcitol
Drug: Native Vitamin D
Drug: Denosumab
Drug: Calcium

First Posted Date: 2023-06-01

Last Posted Date: 2024-02-21

Lead Sponsor: Xi'an Honghui Hospital

Target Recruit Count: 100

Registration Number: NCT05884372

Locations: 🇨🇳
Zeng,Yuhong, Xi'an, China

Adjuvant Therapeutic Effect of Vitamin D on Hashimoto's Thyroiditis

Not yet recruiting

Conditions: Hashimoto Thyroiditis

Interventions: Drug: Vitamin D Drops

First Posted Date: 2023-05-23

Last Posted Date: 2023-05-23

Lead Sponsor: Qianfoshan Hospital

Target Recruit Count: 30

Registration Number: NCT05871957

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: IBI334 E
Drug: IBI334 D
Drug: IBI334 C
Drug: IBI334 B
Drug: IBI334 A
Drug: IBI334 F

First Posted Date: 2023-03-20

Last Posted Date: 2023-11-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 128

Registration Number: NCT05774873

Locations: 🇦🇺
Westmead Hospital, Waratah, New South Wales, Australia

Preoperative Dexamethasone to Improve Quality of Recovery After Laparoscopic Bariatric Surgery

Completed

Conditions: Anesthesia
Analgesia
Acute Pain

Interventions: Drug: Group C
Drug: Group D

First Posted Date: 2023-03-03

Last Posted Date: 2023-09-21

Lead Sponsor: Ondokuz Mayıs University

Target Recruit Count: 60

Registration Number: NCT05752734

Locations: 🇹🇷
Ondokuzmayıs University, Samsun, Turkey

Evaluation of the Efficacy of Vertistop® D and Vertistop® L in the Prevention of BPPV Recurrence

Phase 1

Completed

Conditions: Antioxidants
Benign Paroxysmal Positional Vertigo
Vitamin D

Interventions: Drug: Vertistop® D

First Posted Date: 2023-02-28

Last Posted Date: 2023-02-28

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 126

Registration Number: NCT05748249

Locations: 🇮🇹
Clinica Otorinolaringoiatrica, Roma, Italy

A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Ziltivekimab B
Drug: Ziltivekimab D
Drug: Ziltivekimab C

First Posted Date: 2023-02-10

Last Posted Date: 2025-01-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 267

Registration Number: NCT05721989

Locations: 🇳🇱
ICON - location Groningen, Groningen, Netherlands
🇭🇺
ICON Budapest Phase I Unit, Budapest, Hungary

A HR20031 BE Study on Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: ARM F
Drug: ARM D
Drug: ARM A
Drug: ARM B
Drug: ARM E
Drug: ARM C

First Posted Date: 2023-01-12

Last Posted Date: 2023-04-07

Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT05682495

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

Phase 2

Terminated

Conditions: Psoriasis

Interventions: Drug: VTX958 Dose A
Drug: VTX958 Dose B
Drug: VTX958 Dose C
Drug: Placebo
Drug: VTX958 Dose D

First Posted Date: 2022-12-19

Last Posted Date: 2023-12-28

Lead Sponsor: Ventyx Biosciences, Inc

Target Recruit Count: 222

Registration Number: NCT05655299

Locations: 🇵🇱
Local Site # 616003, Ostrowiec Świętokrzyski, Poland
🇨🇦
Local Site # 124010, Mississauga, Canada
🇨🇦
Local Site # 124008, Québec City, Canada

and more 60 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy